The FDA announced the approval of Lucentis to treat myopic choroidal neovascularization (mCNV) making this the fifth FDA approved indication for Lucentis. This approval is based on the results of the Phase 3 RADIANCE study, which demonstrated that treatment with Lucentis provided superior visual acuity gains in people with mCNV compared to verteporfin photodynamic therapy. (via)
To recap, Lucentis is now FDA approved for
- wet AMD
- macular edema after retinal vein occlusion
- diabetic macular edema
- diabetic retinopathy
- myopic choroidal neovascularization
